AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01081639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitropin beta liquid formulation
Description: Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
Study NCT01286103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg once daily and 150 mg twice daily
Description: Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
Study NCT01286103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg once daily and 50 mg twice daily
Description: Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
Study NCT00784537 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABVD
Description: ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm A (Observation)
Study NCT00784537 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABVD and Radiotherapy
Description: ABVD courses are scheduled every 28 days:~Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15~Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk).
Study NCT00589316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT04109976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Study participants will receive bimekizumab at pre-specified time points.
Study NCT00025155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixabepilone
Description: Given IV
Study NCT02073669 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)
Study NCT00589316 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I 131 Monoclonal Antibody BC8
Description: Given IV (dosimetry dose) or via central line (therapeutic dose)
Study NCT04288700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral propranolol
Description: oral propranolol therapy at a dose of 1 mg/kg/d (Inderal 20 mg/5 mL) in three divided doses. If the child will tolerate the treatment with no side effects, therapy will continue in an outpatient clinic. Blood glucose level will be also measured in a periodic manner during therapy. The dose will be increased gradually to 2 mg/kg/d in three divided doses if there will be no adverse effects from the initial therapy.
Study NCT04288700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Captopril
Description: A test dose of 0.1 mg kg) will be administered orally with pulse rate and blood pressure monitored at 0.5, 1 and 2 h and at each follow up. If the test dose is tolerated, captopril administration will start at 0.15 mg kg) per dose 8-hourly. Pulse rate and blood pressure will be monitored 4-hourly and doses will be withheld if hypotension is documented. After 24 h, the dose will be increased to 0.3 mg kg) per dose 8-hourly .
Study NCT04288700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intralesional propranolol injection
Description: intralesional propranolol injection 1 mg/mL
Study NCT04288700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topical Timolol maleate 0.5% eye drops
Description: To be Applied on the surface of the lesions three times daily
Study NCT04547361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511
Description: E2511 tablets.
Study NCT02337855 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-TSP-2/Alhydrogel/GLA-AF
Description: Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
Study NCT00589316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00589316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT00589316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT00589316 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT04547361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2511 Matched Placebo
Description: Placebo tablets matching E2511 tablets.
Study NCT04507971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MET-3
Description: Human microbiome supplementation derived from bacterial strains isolated from fecal matter and grown in a laboratory environment
Study NCT03704610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: An initial period with 2 injections with infliximab allowing the determination of the primary criteria Then an extension with infliximab with 3 supplementary perfusions
Study NCT03704610 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: An initial period with 2 injections with placebo allowing the determination of the primary criteria Then an extension with infliximab with 5 supplementary perfusions
Study NCT01071824 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse coloplasty pouch (Long limb)
Description: Transverse coloplasty pouch with long limb
Study NCT01071824 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transverse coloplasty pouch (Short limb)
Description: Transverse coloplasty pouch with short limb
Study NCT00109577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCN36 (nutritional supplement)
Description: nutritional supplement
Study NCT00109577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: nutritional supplement
Study NCT01462877 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fenofibrate
Description: Fenofibrate Capsule 200mg qd orally
Study NCT03727412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drugs, Generic (Naprosyn)
Description: naproxen administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
Study NCT03727412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: placebo administration perioperatively in patients with a abdominal aortic aneurysm undergoing endovascular repair
Study NCT02029794 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HPV self-colleciton
Description: Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
Study NCT05220579 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exposure to TOR device
Description: Specific wave spectrum is directed by the TOR device to human tissues affected by the SARS-CoV-2 virus in order to disrupt its activity.
Study NCT05220579 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Exposure to switched off TOR device
Description: The TOR device has screened indicators on the front panel. The device was switched on / off by a medical monitor without the participation of medical personnel and investigators.
Study NCT01541137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
Study NCT01541137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: parecoxib/ valdecoxib
Description: oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
Study NCT01541137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: patient controlled epidural analgesia
Description: epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
Study NCT03691727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tirofiban hydrochloride (AGGRASTAT®)
Description: Participants will have intravenous Aggrastat administered continuously over the course of 7 days in the setting of subarachnoid hemorrhage at least 12 hours post clinically indicated Endovascular Coil Embolization procedure.
Study NCT03691727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
Study NCT03691727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will undergo 2 MRIs administered within 24 hours post Coil Embolization procedure and prior to discharge to monitor for ischemic changes.
Study NCT03691727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Neurological Exam
Description: Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
Study NCT03691727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neurological Exam
Description: Neurological exams will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
Study NCT03691727 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
Study NCT02029794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: visual inspection with acetic acid (VIA)
Study NCT02029794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3-5% acetic acid
Study NCT02271906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
Study NCT02930265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
Study NCT03030365 — intervention group
Intervention type: DEVICE
Intervention: Siemens Biograph mMR PET-MR (3T)
Description: Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.
Study NCT02192632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epiduo once daily with detailed instruction for how to apply it
Study NCT03691727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Quality of Life in Brain Injury - Overall Scale (QOLIBRI-OS) and the Lawton Instrumental Activities of Daily Living (IADL) will be administered at 6 month and 1 year follow up visits.
Study NCT03691727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vital Signs
Description: Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
Study NCT03691727 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vital Signs
Description: Vital signs which include temperature, respiration rate, blood pressure and O2 stats will be done at screening, randomization, days 2-7, discharge, 6 week, 6 month, and one year follow up visits.
Study NCT03691727 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Treatment
Description: Participants will receive standard of care treatment and will not receive study drug.
Study NCT03327948 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axonics Sacral Neuromodulation System (SNM) System
Description: Axonics Sacral Neuromodulation System (SNM) System
Study NCT01080183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient feedback form
Description: patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
Study NCT03906422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Unitek 0.016 orthodontic archwire
Description: Placement of 3M Unitek 0.016 archwire for orthodontic treatment
Study NCT03906422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: 0.016 Ormco 27oC NiTi orthodontic archwire
Description: Placement of 0.016 Ormco 27oC NiTi orthodontic archwire
Study NCT03906422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: 0.016 Ormco 35oC NiTi orthodontic archwire
Description: Placement of 0.016 Ormco 35oC NiTi orthodontic archwire
Study NCT03452137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab intravenous infusion will be administered at a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
Study NCT03452137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo intravenous infusion will be administered a fixed dose on Day 1 of each 21-day cycle for 16 cycles.
Study NCT00641225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBI-087
Description: Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
Study NCT03044626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.~Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)
Study NCT02192632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epiduo- once daily, simple instruction for application
Study NCT02192632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BPO once daily
Study NCT03044626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg fixed dose (q2w)
Study NCT03044626 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab
Description: Nivolumab 240 mg fixed dose (q2w)
Study NCT00794339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 64Cu-ATSM
Study NCT00794339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG
Study NCT02420912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT02420912 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02420912 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT01097512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS703569/gemcitabine
Description: Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle.
Study NCT01097512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS703569/gemcitabine
Description: AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.~Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle.
Study NCT02418832 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Sperm cell aspiration and TEFNA
Description: Testicular Fine Needle Aspiration (TEFNA)
Study NCT02389231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukine-2
Description: Four courses of IL2 ( \[Proleukin, Novartis\]) will be administered subcutaneously for 5 days.~The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.~The other courses of 3 million IU per day will be initiated after a 16 day wash-out.
Study NCT01246635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trufit CB (Cartilage Bone) Implant
Description: Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
Study NCT01246635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture if the knee
Description: Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
Study NCT04436549 — intervention group
Intervention type: PROCEDURE
Intervention: Stab Avulsion of varicose veins
Description: Stab avulsion is a technique to remove varicose veins. In this procedure, several tiny cuts (incisions) are made in the skin through which the varicosed vein is removed. Removed varicose veins will be collected and analyzed.
Study NCT04436549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathologic evaluation of varicose veins
Description: Sample obtained from varicose veins of lower limbs of patients will be collected and immediately fixed in formalin. The tissue fragments will be taken from varicose veins. Subsequently the tissue will be embedded in paraffin and 3-to-4 mm thick sections will be prepared by a microtome. The tissue sections will be processed for histological and immunohistochemical studies of VEGF, MM9, PGP 9.5 AND FRIBRONECTIN. For antibodies the EnVision staining system (Dako EnVision™) will be used. For the analysis of the positive structures detected by immunohistochemistry, a semiquantitative evaluation method will be used.
Study NCT03054766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ranibizumab combined macular laser
Description: subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
Study NCT03054766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: all subjections received 3+PRN ranibizumab injections by BCVA stabilization
Study NCT04062578 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature
Description: The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
Study NCT04062578 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy program of lumbopelvic stabilization and strengthening of the hip region musculature
Description: The intervention program will begin in August, along with the 2019/2020 season, and will finish at the end of the first round (5-6 months). It will be applied to CD Oliver players in three weekly sessions: preventive force, compensatory force and physiotherapy attention. During this intervention period, the SD Huesca players, control group, continued with their usual training program. They will not implement any physiotherapy program like the designed one for the study.
Study NCT00937807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: xenon
Description: Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
Study NCT00937807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sévoflurane
Description: Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
Study NCT04737993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: licocain
Description: pulsed radiofrequency stimulation
Study NCT04737993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency stimulation
Description: pulsed radiofrequency stimulation of joint capsel